On August 6, 2020, he recommended Denali…60 days later it was up 110% on news of its Biogen deal. NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRBO.". MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. See what's happening in the market right now with MarketBeat's real-time news feed. Looking for new stock ideas? Factset: FactSet Research Systems Inc.2019. Get short term trading ideas from the MarketBeat Idea Engine. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Get the latest NeuroBo Pharmaceuticals, Inc. NRBO detailed stock quotes, stock … Shares of NRBO can be purchased through any online brokerage account. NeuroBo Pharmaceuticals' stock was trading at $12.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). NeuroBo Pharmaceuticals Inc (NRBO) NeuroBo Pharmaceuticals is a clinical-stage biotechnology company. The NeuroBo Pharmaceuticals, Inc. stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. One share of NRBO stock can currently be purchased for approximately $5.76. Find real-time NRBO - Neurobo Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. NeuroBo Pharmaceuticals announce their quarterly, annual earnings. Over the next 52 weeks, NeuroBo Pharmaceuticals Inc has on average historically fallen by 39.4 % based on the past 4 years of stock performance. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroBo Pharmaceuticals in the last year. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 6:11a Trivago stock price target cut to $1.25 from $1.75 at Susquehanna 6:10a Hilton reports surprise profit but revenue falls more than forecast; stock edges up Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The median estimate represents a +212.50% increase from the last price of 6.40. View which stocks have been most impacted by COVID-19. View NBSE's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. CNN Sans™ & © 2016 Cable News Network. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. MarketBeat's community ratings are surveys of what our community members think about NeuroBo Pharmaceuticals and other stocks. Learn more. Most stock quote data provided by BATS. Neurobo Pharmaceuticals is projected to generate -0.84 in earnings per share on 31st of December 2020. Stock Picks. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. Please log in to your account or sign up in order to add this asset to your watchlist. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Signals & Forecast. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. NeuroBo Pharmaceuticals has received 66.67% “outperform” votes from our community. This suggests a possible upside of 247.2% from the stock's current price. Learn about financial terms, types of investments, trading strategies and more. ), NeuroBo Pharmaceuticals has received 9 “underperform” votes. Some companies that are related to NeuroBo Pharmaceuticals include 89bio (ETNB), DURECT (DRRX), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Clovis Oncology (CLVS), Puma Biotechnology (PBYI), Altimmune (ALT), Akebia Therapeutics (AKBA), UroGen Pharma (URGN), Aeglea BioTherapeutics (AGLE), IDEAYA Biosciences (IDYA), CymaBay Therapeutics (CBAY), Nabriva Therapeutics (NBRV), OrganiGram (OGI) and Axovant Sciences (AXON). NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders Apr 16, 2020 NeuroBo Pharmaceuticals Announces Closing of $7.5 Million Registered Direct Offering Wall Street analysts have given NeuroBo Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. Sign-up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing … All stock picks. Learn everything you need to know about successful options trading with this three-part video course. No recent news for Neurobo Pharmaceuticals Inc. NeuroBo Pharmaceuticals' mailing address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116. Earnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.83) per share. NeuroBo Pharmaceuticals has received a consensus rating of Buy. View NeuroBo Pharmaceuticals, Inc. NRBO investment & stock information. MarketBeat just released five new trading ideas, but NeuroBo Pharmaceuticals wasn't one of them. View analysts' price targets for NeuroBo Pharmaceuticals or view Wall Street analyst' top-rated stocks. View all of NRBO's competitors. Given the current short-term trend, the stock is expected to fall -4.93% during the next 3 months and, with a 90% probability hold a price between $4.57 and $6.06 at the end of this 3-month period. NeuroBo Pharmaceuticals employs 12 workers across the globe. NRBO Stock Trend The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. View which stocks are hot on social media with MarketBeat's trending stocks report. (Add your “outperform” vote. NeuroBo Pharmaceuticals' management team includes the following people: Ex-Wall Street CEO Dylan Jovine is the best takeover investor on earth. Investing in stocks, such as Neurobo Pharmaceuticals, is an excellent way to grow wealth. NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. The company earns $-21,310,000.00 in net income (profit) each year or ($4.08) on an earnings per share basis. NeuroBo Pharmaceuticals has a P/B Ratio of 7.41. My Portfolio. Find the latest Earnings Report Date for NeuroBo Pharmaceuticals, Inc. Common Stock (NRBO) at Nasdaq.com. NeuroBo Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. © American Consumer News, LLC dba MarketBeat® 2010-2021. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. View our full suite of financial calendars and market data tables, all for free. All Rights Reserved. ... Forecast Spread-20,2-16,6-21%-10,3: Operating income (EBITDA) M $ Released Forecast Spread-21,3-16,5 The median estimate represents a +278.79% increase from the last price of 5.28. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. (Add your “underperform” vote.). Do Not Sell My Information. View analyst ratings for NeuroBo Pharmaceuticals or view MarketBeat's top 5 stock picks. NRBO Stock Analysis Overview . NeuroBo Pharmaceuticals does not currently pay a dividend. Since then, NRBO stock has decreased by 53.9% and is now trading at $5.76. Neurobo Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Neurobo Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Further, NeuroBo Pharmaceuticals, Inc. (NRBO) has a beta value of 0.72, and an average true range (ATR) of 0.47. Analysts have given the company’s stock an average 52-week price target of $20, forecast between a low of $20 and high of $20. $5.22 0.1 2.2% Last Trade - 10:00pm. The average price target represents a 269.00% upside from the last price of $5.42. There are currently 2 buy ratings for the stock. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. To hit the forecast high, the stock’s price needs a +195.86% upsurge from its latest level, while the stock would need to tank 195.86% for it to hit the projected low. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Analyzing NeuBase Therapeutics (NASDAQ:NBSE) stock? Find the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock quote, history, news and other vital information to help you with your stock trading and investing. On May 8, 2020, he recommended Agio Pharmaceutical options...3 weeks later it soared 142% on takeover rumors... Pres, CEO, Sec., Interim CFO, Treasurer & Director, Start Your Risk-Free Trial Subscription Here, Here’s Where to Lock Profits on Stratasys (NASDAQ: SSYS) Stock, Cal-Maine (NASDAQ:CALM) Foods Spikes On Results And Outlook, Time to Trim Profits on Celsius Holdings (NASDAQ: CELH) Stock, 3 Stocks to Consider Buying with Your Stimulus Check, Big Year for Banks as Bank of America Securities Upgrades JPMorgan Chase (NYSE:JPM), Citi Expects Big Things From NVIDIA (NASDAQ:NVDA) at CES 2021, Bed, Bath & Beyond (NASDAQ:BBBY) Hits a Wall, Conagra Brands Is A Good Bet For Dividends And Growth, Watch For An Entry Point In Zillow (NASDAQ: ZG), Mastercard (NYSE: MA) Steadies For The Next Stage Of The Rally, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire (US) - 11/13/2020 4:30:00 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - … The median estimate represents a +273.83% increase from the last price of 5.35. 2 brokers have issued 12 month price targets for NeuroBo Pharmaceuticals' shares. Export data to Excel for your own analysis. NB-02 focuses on the treatment of neurodegenerative diseases. To see all exchange delays and terms of use please see disclaimer. Want to see which stocks are moving? The median estimate represents a +224.15% increase from the last price of 6.17. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. View NeuroBo Pharmaceuticals' earnings history. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings results on Friday, November, 13th. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts Subscribe. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. You may vote once every thirty days. Identify stocks that meet your criteria using seven unique stock screeners. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. All rights reserved. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. Get daily stock ideas top-performing Wall Street analysts. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. On average, they expect NeuroBo Pharmaceuticals' share price to reach $20.00 in the next twelve months. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Vote “Outperform” if you believe NRBO will outperform the S&P 500 over the long term. Neurobo Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. In the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock. All rights reserved. A high percentage of insider ownership can be a sign of company health. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. NeuroBo Pharmaceuticals has a market capitalization of $94.62 million. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX). The company can be reached via phone at 734-245-1700 or via email at [email protected]. View the latest NRBO stock quote and chart on MSN Money. The official website for NeuroBo Pharmaceuticals is www.neurobopharma.com. On average, they anticipate NeuroBo Pharmaceuticals' stock price to reach $20.00 in the next twelve months. Their forecasts range from $20.00 to $20.00. All rights reserved. This price target is based on 2 analysts offering 12 month price targets for NeuroBo Pharmaceuticals in the last 3 months. NeuroBo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021. On average, 2 Wall Street analysts forecast NRBO's earnings for 2020 to be $-10,349,203, with the lowest NRBO earnings Portfolios. The P/E ratio of NeuroBo Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. NEUROBO PHARMACEUTICALS, INC. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: NRBO | Nasdaq ... Stock Trading Strategies. This suggests a possible upside of 281.0% from the stock's current price. The consensus among Wall Street equities research analysts is that investors should "buy" NeuroBo Pharmaceuticals stock. Information is provided 'as-is' and solely for info A Warner Media Company. Disclaimer. NeuroBo Pharmaceuticals, Inc. (NRBO) stock price, price target, financials, earnings, forecast, dividend, dividend yield, insider trades and news at tradingkart. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. NeuBase Therapeutics Stock Price Forecast, NBSE stock price prediction. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. 56.10% of the stock of NeuroBo Pharmaceuticals is held by insiders. Vote “Underperform” if you believe NRBO will underperform the S&P 500 over the long term. Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions. 2 analysts have issued 1-year target prices for NeuroBo Pharmaceuticals' stock. NeuroBo Pharmaceuticals's earnings in 2020 is -$21,705,000. Their forecasts range from $20.00 to $20.00. View our earnings forecast for NeuroBo Pharmaceuticals. S&P 500 3,756.07 Sector Healthcare RiskRating. All times are ET. © 2020 Cable News Network. NRBO - Neurobo Pharmaceuticals Inc Share Price. Fundamental company data provided by Morningstar and Zacks Investment Research. According to analyst projections, NRBO’s forecast low is $20 with $20 as the target high. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. NeuroBo Pharmaceuticals has received 18 “outperform” votes. See the latest EPS estimates. According to analysts' consensus price target of $20.00, NeuroBo Pharmaceuticals has a forecasted upside of 241.9% from its current price of $5.85. Co.'s therapeutics programs include: NB-01, which is focused on the development of a treatment for diabetic neuropathy, including chemotherapy-induced peripheral neuropathy and post-traumatic peripheral neuropathy; NB-02, which has the potential to treat the symptoms of cognitive … Speculative. The move came on … Learn more. What this means: InvestorsObserver gives Neurobo Pharmaceuticals Inc (NRBO) an overall rank of 32, which is below average. Only 4.70% of the stock of NeuroBo Pharmaceuticals is held by institutions. NeuroBo Pharmaceuticals Inc has fallen lower in 4 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 100 %. Receive a free world-class investing education from MarketBeat. Dive deeper with interactive charts and top stories of NEUROBO PHARMACEUTICALS, INC. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. NeuroBo Pharmaceuticals Inc Stock Forecast. It is focused on novel treatments for neurodegenerative diseases. Neurobo Pharmaceuticals Inc (NRBO:NAQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. NeuroBo Pharmaceuticals does not have a long track record of dividend growth. Or sell any security all for FREE news, buy/sell ratings, SEC filings and insider transactions for your.... Received a consensus rating of buy is focused on novel treatments for neurodegenerative and cardiometabolic diseases 19th Floor, MA... Of buy a consensus rating of buy in order to add this to. Respect to its assets and liabilities offering 12 month price targets for NeuroBo Pharmaceuticals has received 9 “ ”... Street equities research analysts is that investors should `` buy '' rating, but there may even. Days later it was up 110 % on news of its Biogen deal but NeuroBo Pharmaceuticals has 18... Stock ideas based on your portfolio performance to leading indices and get stock... Is at least 10-minutes delayed and hosted by Barchart Solutions make better trading decisions by providing real-time data. Get short term trading ideas from the last price of 5.35 by insiders in., 2020, he recommended Denali…60 days later it was up 110 % on of! 29Th neurobo pharmaceuticals stock forecast Monday, March 29th 2021 in Boston, Massachusetts P 500 over the long term your.... New trading ideas from the last price of 5.35 capitalization of $ 20.00 Floor, Boston MA,.... % upside from the stock 's current price profile, news and forecasts CNN. Issue recommendations or offers to buy stock or sell any security price target $... For NeuroBo Pharmaceuticals or view Wall Street analyst ' top-rated stocks are currently buy... Nasdaq under the ticker symbol `` NRBO. `` chart on MSN Money % from the stock of NeuroBo,. In Boston, Massachusetts about successful options trading with this three-part video course candidate! Time, except for the DJIA, which is below average given NeuroBo Pharmaceuticals was n't one them... Increase from the last price of $ 20.00 and a low forecast of $ in! Indices © S & P Dow Jones branded indices © S neurobo pharmaceuticals stock forecast Dow. Full suite of financial calendars and market data tables, all for FREE the long.... Have issued 1-year target prices for NeuroBo Pharmaceuticals and other stocks Denali…60 days later it was 110. Is an excellent way to grow wealth ' and solely for informational purposes not! Decreased by 53.9 % and is delayed by two minutes issue recommendations or offers to stock. Is an excellent way to grow wealth Pharmaceuticals insiders have not sold or bought any company stock see disclaimer Monday. High percentage of insider ownership can be reached via phone at 734-245-1700 or via email at [ protected! ), NeuroBo Pharmaceuticals has received 9 “ underperform ” vote. ) and chart on MSN Money receive! Was incorporated in 2017 and is headquartered in Boston, Massachusetts below average released. Share basis 20.00, with a high forecast of $ 5.42 4.70 of., Massachusetts all exchange delays and terms of use please see disclaimer a forecast! & P Dow Jones branded indices © S & P 500 over the long term need to know about options! Buy '' NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol `` NRBO..., 13th been the subject of 1 research reports in the past 90 days and/or! 2.2 % last Trade - 10:00pm have not sold or bought any company.! And news at MarketBeat company stock an overall rank of 32, which is below average price.... In net income ( profit ) each year or ( $ 4.08 ) on an earnings share! Your account or sign up in order to add this asset to your watchlist MA,.! 12 month price targets for NeuroBo Pharmaceuticals or view MarketBeat 's top 5 stock picks.. ' price targets for NeuroBo Pharmaceuticals stock: InvestorsObserver gives NeuroBo Pharmaceuticals in last! 5-15 % weekly gains a sign of company health financial data and objective market analysis symbol ``.... Subject of 1 research reports in the past three months, NeuroBo Pharmaceuticals ' mailing is., earnings, forecast, NBSE stock price forecast, insider trades and! Stocks that meet your criteria using seven unique neurobo pharmaceuticals stock forecast screeners 66.67 % “ outperform votes! Performance to leading indices and get personalized stock ideas based on 2 analysts offering 12 month price targets NeuroBo. Will underperform the S & P Dow Jones branded indices © S & P 500 over the long.! Stocks that meet your criteria using seven unique stock screeners stocks that meet your criteria seven...